Literature DB >> 33614487

Prediction of Pathological Upgrading at Radical Prostatectomy in Prostate Cancer Eligible for Active Surveillance: A Texture Features and Machine Learning-Based Analysis of Apparent Diffusion Coefficient Maps.

Jinke Xie1, Basen Li1, Xiangde Min1, Peipei Zhang1, Chanyuan Fan1, Qiubai Li2, Liang Wang1.   

Abstract

OBJECTIVE: To evaluate a combination of texture features and machine learning-based analysis of apparent diffusion coefficient (ADC) maps for the prediction of Grade Group (GG) upgrading in Gleason score (GS) ≤6 prostate cancer (PCa) (GG1) and GS 3 + 4 PCa (GG2).
MATERIALS AND METHODS: Fifty-nine patients who were biopsy-proven to have GG1 or GG2 and underwent MRI examination with the same MRI scanner prior to transrectal ultrasound (TRUS)-guided systemic biopsy were included. All these patients received radical prostatectomy to confirm the final GG. Patients were divided into training cohort and test cohort. 94 texture features were extracted from ADC maps for each patient. The independent sample t-test or Mann-Whitney U test was used to identify the texture features with statistically significant differences between GG upgrading group and GG non-upgrading group. Texture features of GG1 and GG2 were compared based on the final pathology of radical prostatectomy. We used the least absolute shrinkage and selection operator (LASSO) algorithm to filter features. Four supervised machine learning methods were employed. The prediction performance of each model was evaluated by area under the receiver operating characteristic curve (AUC). The statistical comparison between AUCs was performed.
RESULTS: Six texture features were selected for the machine learning models building. These texture features were significantly different between GG upgrading group and GG non-upgrading group (P < 0.05). The six features had no significant difference between GG1 and GG2 based on the final pathology of radical prostatectomy. All machine learning methods had satisfactory predictive efficacy. The diagnostic performance of nearest neighbor algorithm (NNA) and support vector machine (SVM) was better than random forests (RF) in the training cohort. The AUC, sensitivity, and specificity of NNA were 0.872 (95% CI: 0.750-0.994), 0.967, and 0.778, respectively. The AUC, sensitivity, and specificity of SVM were 0.861 (95%CI: 0.732-0.991), 1.000, and 0.722, respectively. There had no significant difference between AUCs in the test cohort.
CONCLUSION: A combination of texture features and machine learning-based analysis of ADC maps could predict PCa GG upgrading from biopsy to radical prostatectomy non-invasively with satisfactory predictive efficacy.
Copyright © 2021 Xie, Li, Min, Zhang, Fan, Li and Wang.

Entities:  

Keywords:  Gleason score; active surveillance; machine learning; magnetic resonance imaging; prostatic neoplasms

Year:  2021        PMID: 33614487      PMCID: PMC7890009          DOI: 10.3389/fonc.2020.604266

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  46 in total

1.  Correlations between Apparent Diffusion Coefficient and Gleason Score in Prostate Cancer: A Systematic Review.

Authors:  Alexey Surov; Hans Jonas Meyer; Andreas Wienke
Journal:  Eur Urol Oncol       Date:  2019-01-23

2.  Global cancer incidence in older adults, 2012 and 2035: A population-based study.

Authors:  Sophie Pilleron; Diana Sarfati; Maryska Janssen-Heijnen; Jérôme Vignat; Jacques Ferlay; Freddie Bray; Isabelle Soerjomataram
Journal:  Int J Cancer       Date:  2018-10-30       Impact factor: 7.396

3.  Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.

Authors:  Alessandro Morlacco; John C Cheville; Laureano J Rangel; Derek J Gearman; R Jeffrey Karnes
Journal:  Eur Urol       Date:  2016-08-27       Impact factor: 20.096

4.  Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort.

Authors:  Jonathan L Wright; Claudia A Salinas; Daniel W Lin; Suzanne Kolb; Joseph Koopmeiners; Ziding Feng; Janet L Stanford
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

5.  Correlation between apparent diffusion coefficient value on diffusion-weighted MR imaging and Gleason score in prostate cancer.

Authors:  X Wu; P Reinikainen; A Vanhanen; M Kapanen; T Vierikko; P Ryymin; S Hyödynmaa; P-L Kellokumpu-Lehtinen
Journal:  Diagn Interv Imaging       Date:  2016-09-27       Impact factor: 4.026

6.  Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Predict Gleason Score Upgrading in Intermediate-Risk 3 + 4 = 7 Prostate Cancer.

Authors:  Radu Rozenberg; Rebecca E Thornhill; Trevor A Flood; Shaheed W Hakim; Christopher Lim; Nicola Schieda
Journal:  AJR Am J Roentgenol       Date:  2016-02-02       Impact factor: 3.959

7.  Predictors of pathological upgrading in low-risk prostate cancer patients without hypointense lesions on an apparent diffusion coefficient map of multiparametric magnetic resonance imaging.

Authors:  Minyong Kang; Byeongdo Song; Injae Lee; Sang Eun Lee; Seok-Soo Byun; Sung Kyu Hong
Journal:  World J Urol       Date:  2016-04-13       Impact factor: 4.226

8.  Machine learning classifiers can predict Gleason pattern 4 prostate cancer with greater accuracy than experienced radiologists.

Authors:  Michela Antonelli; Edward W Johnston; Nikolaos Dikaios; King K Cheung; Harbir S Sidhu; Mrishta B Appayya; Francesco Giganti; Lucy A M Simmons; Alex Freeman; Clare Allen; Hashim U Ahmed; David Atkinson; Sebastien Ourselin; Shonit Punwani
Journal:  Eur Radiol       Date:  2019-06-11       Impact factor: 5.315

Review 9.  Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options.

Authors:  Martin G Sanda; Jeffrey A Cadeddu; Erin Kirkby; Ronald C Chen; Tony Crispino; Joann Fontanarosa; Stephen J Freedland; Kirsten Greene; Laurence H Klotz; Danil V Makarov; Joel B Nelson; George Rodrigues; Howard M Sandler; Mary Ellen Taplin; Jonathan R Treadwell
Journal:  J Urol       Date:  2017-12-15       Impact factor: 7.450

10.  "Textural analysis of multiparametric MRI detects transition zone prostate cancer".

Authors:  Harbir S Sidhu; Salvatore Benigno; Balaji Ganeshan; Nikos Dikaios; Edward W Johnston; Clare Allen; Alex Kirkham; Ashley M Groves; Hashim U Ahmed; Mark Emberton; Stuart A Taylor; Steve Halligan; Shonit Punwani
Journal:  Eur Radiol       Date:  2016-09-12       Impact factor: 5.315

View more
  4 in total

1.  An MRI-based radiomics-clinical nomogram for the overall survival prediction in patients with hypopharyngeal squamous cell carcinoma: a multi-cohort study.

Authors:  Juan Chen; Shanhong Lu; Yitao Mao; Lei Tan; Guo Li; Yan Gao; Pingqing Tan; Donghai Huang; Xin Zhang; Yuanzheng Qiu; Yong Liu
Journal:  Eur Radiol       Date:  2021-10-19       Impact factor: 7.034

Review 2.  Quality in MR reporting (include improvements in acquisition using AI).

Authors:  Liang Wang; Daniel J Margolis; Min Chen; Xinming Zhao; Qiubai Li; Zhenghan Yang; Jie Tian; Zhenchang Wang
Journal:  Br J Radiol       Date:  2022-02-04       Impact factor: 3.039

3.  The Dilemma of Misclassification Rates in Senior Patients With Prostate Cancer, Who Were Treated With Robot-Assisted Radical Prostatectomy: Implications for Patient Counseling and Diagnostics.

Authors:  Nikolaos Liakos; Joern H Witt; Pawel Rachubinski; Sami-Ramzi Leyh-Bannurah
Journal:  Front Surg       Date:  2022-02-16

4.  Machine Learning-Based Prediction of Pathological Upgrade From Combined Transperineal Systematic and MRI-Targeted Prostate Biopsy to Final Pathology: A Multicenter Retrospective Study.

Authors:  Junlong Zhuang; Yansheng Kan; Yuwen Wang; Alessandro Marquis; Xuefeng Qiu; Marco Oderda; Haifeng Huang; Marco Gatti; Fan Zhang; Paolo Gontero; Linfeng Xu; Giorgio Calleris; Yao Fu; Bing Zhang; Giancarlo Marra; Hongqian Guo
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.